# ▼Abaloparatide (Eladynos) for osteoporosis.

> PubMed lists PMID 40588314 in Drug and therapeutics bulletin as Journal Article, with publication-date metadata of 2025-06-30 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40588314-abaloparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-09-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40588314-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-40588314-abaloparatide-v1.json
- Content SHA-256: `9616f94978984052412386a4bf308029bbbf59c958fe690241a03805cafdb2e3`

## Claims and source pins

### Headline

▼Abaloparatide (Eladynos) for osteoporosis. ([`pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce`](#source-pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce))

### Summary

PubMed lists PMID 40588314 in Drug and therapeutics bulletin as Journal Article, with publication-date metadata of 2025-06-30 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce`](#source-pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce))

### Paragraph 1

PubMed lists PMID 40588314 in Drug and therapeutics bulletin as Journal Article, with publication-date metadata of 2025-06-30 (day precision). PeptideScanner associated the retained record with the identity slug abaloparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce`](#source-pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce`](#source-pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce))

## Sources

<a id="source-pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce"></a>
- **▼Abaloparatide (Eladynos) for osteoporosis. · retained source version 1:2025-09-11:current:9a8831c827ce9a09c441fc4c5892c437f6a3e79f7208e6fc1e0a41aeb9bc83eb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40588314/) (`pubmed-observation-pmid-40588314-2025-09-11-9a8831c827ce`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "▼Abaloparatide (Eladynos) for osteoporosis." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-40588314-abaloparatide-v1.json SHA-256: 9616f94978984052412386a4bf308029bbbf59c958fe690241a03805cafdb2e3.